Hormone replacement therapy — estrogen-based therapy in women and testosterone replacement therapy (TRT) in men — is common, genuinely helpful for the right person, and has a real, evidence-based relationship with cardiovascular risk that's more nuanced than a flat "good" or "bad." The details matter: who's taking it, why, at what age, by what route, and with what monitoring. This page covers both, since the cardiovascular questions are different for each.
Hormone Replacement Therapy in Women (Menopausal HRT)
Menopausal hormone therapy (estrogen alone, or estrogen plus a progestin for women with a uterus) is prescribed mainly for menopausal symptoms — hot flashes, night sweats, vaginal dryness, sleep disruption — not as a cardiovascular treatment. But its cardiovascular effects have been studied extensively, and the picture depends heavily on timing.
- The "timing hypothesis" — starting HRT within about 10 years of menopause, or before age 60, appears to have a neutral-to-favorable cardiovascular risk profile for most healthy women. Starting it more than 10 years after menopause, or later in life, is associated with a higher risk of heart disease and stroke — likely because it's acting on arteries that already have more established atherosclerosis.
- Route matters — oral estrogen carries a higher risk of blood clots and stroke than transdermal (patch or gel) estrogen, because oral estrogen is processed through the liver first, which affects clotting factors. Transdermal routes are often preferred, especially for women with any additional cardiovascular risk factors.
- It is not a preventive heart treatment — current guidelines do not recommend starting or continuing HRT specifically to prevent heart disease, even in women who fall in the favorable timing window. It's prescribed for symptom relief, with the cardiovascular profile as one factor in the decision, not the reason for it.
- Who should generally avoid it — women with known cardiovascular disease, a history of blood clots, a history of stroke, uncontrolled high blood pressure, or certain hormone-sensitive cancers are generally advised against systemic HRT, or need a very individualized discussion with both their gynecologist and cardiologist.
(See Women and Cardiovascular Disease for how menopause itself, independent of HRT, affects cardiovascular risk.)
Testosterone Replacement Therapy in Men
TRT is prescribed for men with documented hypogonadism — clinically low testosterone confirmed on bloodwork, along with symptoms like fatigue, low libido, or loss of muscle mass — not simply for normal age-related decline without symptoms or lab confirmation.
- The safety question has shifted with better evidence — early observational studies raised concern about cardiovascular risk with TRT, which led to years of caution and conflicting guidance. The TRAVERSE trial (2023), a large randomized trial designed specifically to answer this question in men with hypogonadism and existing cardiovascular risk factors, found no increased risk of heart attack, stroke, or cardiovascular death compared to placebo — a reassuring, practice-changing result for appropriately selected patients.
- But it wasn't risk-free — the same trial found a higher rate of atrial fibrillation, blood clots (pulmonary embolism), and acute kidney injury in the testosterone group, which is why monitoring during treatment still matters.
- What gets monitored — hematocrit (testosterone can thicken the blood by stimulating red blood cell production, raising clot risk if it climbs too high), blood pressure, and lipid levels, typically checked periodically after starting therapy.
- It's not indicated for otherwise-healthy aging — using testosterone to counteract normal age-related decline without documented hypogonadism isn't supported by current evidence and carries risk without a clearly established benefit.
Common Ground for Both
- Get a baseline cardiovascular evaluation before starting either therapy if you have any known heart disease, risk factors, or your care team recommends it
- Make sure whoever prescribes your hormone therapy knows your full cardiovascular history, and vice versa — your cardiologist should know you're on it
- Periodic monitoring isn't optional bureaucracy — it's specifically designed to catch the small number of complications these therapies can cause before they become serious
- Neither therapy should be started or continued purely to "protect your heart" — that's not what the evidence supports for either one
When to Call Your Doctor
Call if you notice new swelling in one leg, unusual bruising or bleeding, new palpitations, or unexplained shortness of breath while on either therapy. Go to the ER for chest pain, sudden severe shortness of breath, or signs of stroke (facial drooping, arm weakness, slurred speech).
Common Questions
Does HRT protect my heart if I start it early enough?
It may be cardiovascular-neutral or mildly favorable in the right timing window, but it's not prescribed or recommended as a heart-protective treatment — the decision should be based on your symptoms and overall risk profile, discussed with your doctor.
Is TRT safe for my heart?
For men with documented hypogonadism, current evidence (including the large TRAVERSE trial) is reassuring regarding heart attack and stroke risk, though it does carry a real risk of atrial fibrillation, blood clots, and thickened blood that requires monitoring.
Can I take hormone therapy if I've already had a heart attack or have heart failure?
This requires an individualized discussion between you, your cardiologist, and your prescribing physician — it isn't a blanket yes or no.
Does the type of estrogen or delivery method matter?
Yes — transdermal estrogen generally carries a lower clotting risk than oral estrogen, which is one of several factors your doctor will weigh.